Alexander Drilon

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

5.4Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0467

Top 4%

5.0DataRank

Top 4%401 citations

Moriah H. Nissan, Hongxin Zhang, Ritika Kundra, Subhiksha Nandakumar, Calvin Lu +21 more

Papers

Driven by 90 papers — median percentile 58. Top paper: “Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer”.

Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0467

Top 4%

5.0DataRank

Top 4%401 citations

Moriah H. Nissan, Hongxin Zhang, Ritika Kundra, Subhiksha Nandakumar, Calvin Lu +21 more

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00541-1

N/A

5.0DataRank · unranked

426 citations

Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss +10 more

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

New England Journal of Medicine(2023)10.1056/nejmoa2309457

N/A

4.6DataRank · unranked

218 citations

Benjamin Solomon, Herbert H. Loong, Keunchil Park, M. Pérol, Edurne Arriola +19 more

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800

N/A

3.5DataRank · unranked

140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Communications Biology(2020)10.1038/s42003-020-01508-w

N/A

2.2DataRank · unranked

63 citations

Nicolle E. Hofmann, Bryan D. Smith, Igor Odintsov, Morana Vojnic, Irina Linkov +10 more

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3321

N/A

1.9DataRank · unranked

48 citations

Adam J. Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa +17 more

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

JCO Precision Oncology(2022)10.1200/po.21.00418

N/A

1.9DataRank · unranked

87 citations

Daniel S.W. Tan, Ulrik Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel +10 more

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist(2022)10.1093/oncolo/oyac080

N/A

1.7DataRank · unranked

49 citations

Christina S. Baik, Jessica R. Bauman, Jill Gilbert, Marcia S. Brose, Juneko E. Grilley‐Olson +13 more

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Investigational New Drugs(2021)10.1007/s10637-020-01035-9

N/A

1.2DataRank · unranked

32 citations

D. Liu, Michael Offin, Cecilia Lezcano, Jean Torrisi, Sheldon L. Brownstein +13 more

Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.9009

N/A

0.998DataRank · unranked

19 citations

Emily S. Lebow, Yonina R. Murciano‐Goroff, Gowtham Jayakumaran, Ronglai Shen, A. Rose Brannon +15 more

Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.01.008

N/A

0.982DataRank · unranked

21 citations

Christina J. Falcon, Sabrina T. Lin, Christina Chacko, Grace Grimaldi, Dazhi Liu +4 more

Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.10.004

N/A

0.941DataRank · unranked

34 citations

Erika Gedvilaite, Ryan Ptashkin, Jason C. Chang, John Ziegler, Douglas A. Mata +14 more

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Cancer(2023)10.1002/cncr.35036

N/A

0.937DataRank · unranked

25 citations

Lin Shen, David S. Hong, Ray McDermott, Vicki L. Keedy, Michela Casanova +19 more

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature Medicine(2020)10.1038/s41591-019-0716-8

N/A

0.898DataRank · unranked

397 citations

Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon +16 more

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Nature Medicine(2022)10.1038/s41591-022-02047-z

N/A

0.792DataRank · unranked

195 citations

Emily S. Lebow, Randy Yeh, Jeeban Paul Das, Azadeh Namakydoust, Paul K. Paik +67 more

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1119

N/A

0.770DataRank · unranked

169 citations

Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar +17 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0.724DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Rare molecular subtypes of lung cancer

Nature Reviews Clinical Oncology(2023)10.1038/s41571-023-00733-6

N/A

0.721DataRank · unranked

121 citations

Soo‐Ryum Yang, Emiliano Cocco, Alexander Drilon, Guilherme Harada

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0423

N/A

0.700DataRank · unranked

105 citations

Michael Offin, Christina J. Falcon, David N. Brown, Brian Houck‐Loomis, Fanli Meng +21 more

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

Nature Communications(2022)10.1038/s41467-022-34109-8

N/A

0.606DataRank · unranked

56 citations

Alison M. Schram, Ezra Y. Rosen, Helen Won, Yixiao Gong, Anne Marie Noronha +11 more

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0231

N/A

0.587DataRank · unranked

49 citations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson +23 more

Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.01488

N/A

0.542DataRank · unranked

36 citations

Meagan Montesion, Smruthy Sivakumar, Caryn Hale, Anita S. Bowman, Ayyüce Begüm Bektaş +29 more

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors

The Oncologist(2025)10.1093/oncolo/oyaf017

N/A

0.473DataRank · unranked

11 citations

Yonina R. Murciano‐Goroff, Antoine Desîlets, Guilherme Harada, Michael A. Postow, Margaret K. Callahan +9 more

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3981

N/A

0.472DataRank · unranked

12 citations

Soo‐Ryum Yang, Jessica J. Tao, Antoine Desîlets, Eli L. Diamond, Clare Wilhelm +18 more

35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer

ESMO Open(2024)10.1016/j.esmoop.2024.102614

Top 42%

0.452DataRank

Top 42%8 citations

Alexander Drilon, Benjamin Solomon, Pascale Tomasini, Herbert H. Loong, Filippo de Braud +7 more

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

Disease Models & Mechanisms(2020)10.1242/dmm.047779

N/A

0.385DataRank · unranked

12 citations

Igor Odintsov, Roger S. Smith, Kota Ishizawa, Allan J. W. Liu, Lukas Delasos +17 more

MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1 -Fusion-Positive Lung Cancer

Molecular Cancer Research(2022)10.1158/1541-7786.mcr-22-0025

N/A

0.373DataRank · unranked

11 citations

Igor Odintsov, Adam J. Schoenfeld, Evan Siau, Marissa S. Mattar, Elisa de Stanchina +7 more

Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer

JCO Precision Oncology(2024)10.1200/po.24.00216

N/A

0.345DataRank · unranked

9 citations

Angela BY Hui, José de Arimateia Batista Araújo-Filho, Emily G. Hamilton, Jacob J. Chabon, Everett J. Moding +20 more

Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3025

N/A

0.345DataRank · unranked

9 citations

Vicky Makker, Darren J. Buonocore, Ronglai Shen, Rona Yaeger, Michelle S. Ginsberg +15 more

Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21098

N/A

0.330DataRank · unranked

8 citations

Debra A. Goldman, Sabrina T. Lin, Darren J. Buonocore, Jianjiong Gao, Jason C. Chang +15 more

Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies

JAMA Oncology(2025)10.1001/jamaoncol.2024.5364

N/A

0.292DataRank · unranked

6 citations

Monica F. Chen, Anne Marie Noronha, Kristalla Panageas, Maggie Reynolds, Kaelyn Kohlasch +22 more

Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.11.010

N/A

0.269DataRank · unranked

5 citations

Rohit Thummalapalli, Christopher A. Febres‐Aldana, Daniel M. Muldoon, Christina J. Falcon, Amanda Pupo +18 more

Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9067

N/A

0.269DataRank · unranked

5 citations

Angela B. Hui, Jacob J. Chabon, Everett J. Moding, Emily S. Lebow, José de Arimateia Batista Araújo-Filho +15 more

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

European Journal of Cancer(2024)10.1016/j.ejca.2024.114257

N/A

0.269DataRank · unranked

5 citations

Tatiana Erazo, Justin Jee, Andrea Arfè, Avantika Gupta, Luke Pike +28 more

An Ascendant Challenge: Central Nervous System Metastases in ALK + Lung Cancers

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0341

N/A

0DataRank · unranked

3 citations

Guilherme Harada, Alexander Drilon, Yonina R. Murciano‐Goroff

Mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3104

N/A

0DataRank · unranked

17 citations

Noura J. Choudhury, Alison M. Schram, Ezra Y. Rosen, Yonina R. Murciano‐Goroff, Christina J. Falcon +13 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004

N/A

0DataRank · unranked

57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more

Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9080

N/A

0DataRank · unranked

3 citations

Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm +11 more

Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3109

N/A

0DataRank · unranked

1 citations

Christina J. Falcon, Sabrina T. Lin, Aradhika Dhawan, Grace Grimaldi, Dazhi Liu +5 more

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3135

N/A

0DataRank · unranked

0 citations

Yonina R. Murciano‐Goroff, Justin Jee, Maria E. Arcila, Darren J. Buonocore, Jianjiong Gao +15 more

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature Communications(2022)10.1038/s41467-022-28848-x

N/A

0DataRank · unranked

114 citations

Helen Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong +27 more

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

Nature Medicine(2022)10.1038/s41591-022-01786-3

N/A

0DataRank · unranked

129 citations

Jiaqi Ma, Martin G. Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi +17 more

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Nature Communications(2022)10.1038/s41467-022-30496-0

N/A

0DataRank · unranked

194 citations

Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard Ferraro, Sherri Z. Millis +38 more

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0361

N/A

0DataRank · unranked

68 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity

Cancers(2023)10.3390/cancers15164146

N/A

0DataRank · unranked

43 citations

Matteo Repetto, Soo‐Ryum Yang, Eric J. Sherman, Alexander Drilon, Antoine Desîlets

Precision Oncology: 2023 in Review

Cancer Discovery(2023)10.1158/2159-8290.cd-23-1194

N/A

0DataRank · unranked

41 citations

Sarah P. Suehnholz, Alexander Drilon, Debyani Chakravarty, Yonina R. Murciano‐Goroff

BRCA reversion mutations in a pan-cancer cohort to reveal BRCA-dependence in select noncanonical BRCA-mutant histologies.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3012

N/A

0DataRank · unranked

0 citations

Alison M. Schram, Ezra Y. Rosen, Yelena Y. Janjigian, Michael F. Berger, Mark T.A. Donoghue +3 more

Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to “False” Decreases in Renal Function

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.09.1444

N/A

0DataRank · unranked

32 citations

Guilherme Harada, Dazhi Liu, Ray DeMatteo, Christina J. Falcon, Clare Wilhelm +4 more

Immunogenicity of a public neoantigen derived from mutated PIK3CA

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.04.08.439061

N/A

0DataRank · unranked

3 citations

Jiaqi Ma, Martin G. Klatt, Friederike Dündar, Chaitanya Bandlamudi, Pedram Razavi +12 more

Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy

Ophthalmology Retina(2021)10.1016/j.oret.2021.06.001

N/A

0DataRank · unranked

14 citations

Julia Canestraro, Dianna Haggag-Lindgren, James J. Harding, Eli L. Diamond, Alexander Drilon +5 more

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.05.007

N/A

0DataRank · unranked

20 citations

Igor Odintsov, Vladimir Markov, Rebecca Caeser, Paweł Sobczuk, Sam E. Tischfield +14 more

Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib

Lung Cancer(2023)10.1016/j.lungcan.2023.02.005

N/A

0DataRank · unranked

8 citations

Jordan Eichholz, Emily S. Lebow, Jessica Flynn, Zhigang Zhang, Henry Walch +14 more

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer

Frontiers in Oncology(2023)10.3389/fonc.2023.1178313

N/A

0DataRank · unranked

9 citations

Lynette M. Sholl, Sanja Đačić, Michael C. Fishbein, Yonina R. Murciano‐Goroff, Ravi Rajaram +5 more

Decision‐making as discovery: Vetting clinical research in a leading precision oncology service

Sociology of Health & Illness(2023)10.1111/1467-9566.13719

N/A

0DataRank · unranked

5 citations

Jonah Campbell, Alexander Drilon, Peter Keating, Jess B. Polk, Alberto Cambrosio

Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib

JCO Precision Oncology(2023)10.1200/po.23.00295

N/A

0DataRank · unranked

5 citations

Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh +16 more

Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer

Clinical Lung Cancer(2023)10.1016/j.cllc.2023.12.001

N/A

0DataRank · unranked

5 citations

Alexander Drilon, Chao‐Hua Chiu, Herbert H. Loong, Salvatore Siena, Maciej Krzakowski +5 more

Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?

Ocular Oncology and Pathology(2023)10.1159/000529127

N/A

0DataRank · unranked

3 citations

William Foulsham, Julia Canestraro, James J. Harding, Eli L. Diamond, David H. Abramson +2 more

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100606

N/A

0DataRank · unranked

2 citations

Andrew Chow, Alexander Drilon, Or Kalchiem‐Dekel, Sunanjay Bajaj

Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors

JCO Precision Oncology(2023)10.1200/po.23.00217

N/A

0DataRank · unranked

2 citations

David S. Hong, Alexander Drilon, Marcia S. Brose

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100187

N/A

0DataRank · unranked

33 citations

Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang +13 more

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3062

N/A

0DataRank · unranked

2 citations

Guilherme Harada, Noura J. Choudhury, Casey Savin, Ronak Shah, Michael F. Berger +2 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1

N/A

0DataRank · unranked

0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Data from Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes

(2023)10.1158/1078-0432.c.6530487.v1

N/A

0DataRank · unranked

0 citations

Michael Offin, Christina J. Falcon, David N. Brown, Brian Houck‐Loomis, Fanli Meng +21 more

In Reply to “Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC”

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.02.011

N/A

0DataRank · unranked

0 citations

Sabrina T. Lin, Clare Wilhelm, Alexia Iasonos, Alexander Drilon, Yonina R. Murciano‐Goroff

Data from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

(2023)10.1158/2159-8290.c.6679570

N/A

0DataRank · unranked

0 citations

Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish M. Gadgeel, Dale Nepert +20 more

Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.03.023

N/A

0DataRank · unranked

40 citations

Jason C. Chang, Charles Leduc, Kay See Tan, Snjezana Doğan, Ryma Benayed +8 more

Two decades of advances in clinical oncology — lessons learned and future directions

Nature Reviews Clinical Oncology(2024)10.1038/s41571-024-00945-4

N/A

0DataRank · unranked

23 citations

Christopher M. Booth, Éduardo Bruera, Markus W. Büchler, Alexander Drilon, Terry J. Fry +14 more

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future

Drugs(2024)10.1007/s40265-024-02040-5

N/A

0DataRank · unranked

17 citations

Matteo Repetto, Clare Wilhelm, Alexander Drilon, Monica F. Chen

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

British Journal of Cancer(2024)10.1038/s41416-024-02760-1

N/A

0DataRank · unranked

13 citations

Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick, Elisa de Stanchina +17 more

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.08.654

N/A

0DataRank · unranked

1 citations

Filippo de Braud, Alexander Drilon, Robert C. Doebele, Manish R. Patel, Byoung Chul Cho +15 more

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

npj Precision Oncology(2024)10.1038/s41698-024-00663-1

N/A

0DataRank · unranked

9 citations

Matteo Repetto, Clare Keddy, Katelyn S. Nicholson, Kristen L. Jones, Kevin D. Nusser +5 more

542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients

Annals of Oncology(2020)10.1016/j.annonc.2020.08.656

N/A

0DataRank · unranked

3 citations

David S. Hong, Andrew Briggs, Jesús García‐Foncillas, Ulrik Lassen, Gilles Vassal +9 more

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients

Annals of Oncology(2020)10.1016/j.annonc.2020.04.008

N/A

0DataRank · unranked

33 citations

Bo Liu, Alison M. Schram, Pedram Razavi, Stephen M. Lagana, Y. Zhang +10 more

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.01.16.575901

N/A

0DataRank · unranked

3 citations

Matteo Repetto, Clare Keddy, Katelyn S. Nicholson, Kristen L. Jones, Kevin D. Nusser +5 more

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0571

N/A

0DataRank · unranked

70 citations

Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman +29 more

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2424286122

N/A

0DataRank · unranked

9 citations

Ezra Y. Rosen, Malvika Sharma, M. Dorso, Nicholas Mai, Corina Amor +22 more

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0620

N/A

0DataRank · unranked

8 citations

Justin Jee, Alexander Drilon, Andreas M. Heilmann, Justin M. Allen, Alexa B. Schrock +3 more

Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.07.009

N/A

0DataRank · unranked

5 citations

Julia Rotow, Maria E. Arcila, M. Hatton, Lynette M. Sholl, Christian Rolfo +35 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0DataRank · unranked

5 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

Clinical and Translational Medicine(2025)10.1002/ctm2.70338

N/A

0DataRank · unranked

3 citations

Valentina Foglizzo, Jason Chang, Natasha Rekhtman, Ann Elizabeth Sisk, Jamie Gibson +20 more

Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100792

N/A

0DataRank · unranked

3 citations

Rose Parisi, Guilherme Harada, Andrea P. Moy, George Dranitsaris, Jasmine H. Francis +7 more

Leveraging RNA from DNA Extraction Lysate to Rescue “Insufficient” Samples for More Comprehensive Genomic Profiling in Patients with Scant Tumor Specimens

Journal of Molecular Diagnostics(2025)10.1016/j.jmoldx.2025.04.005

N/A

0DataRank · unranked

0 citations

Sara DiNapoli, Kerry Mullaney, Alison M. Urvalek, Minji K. Uh, Purvil Sukhadia +14 more

A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100857

N/A

0DataRank · unranked

0 citations

Fernando C. Santini, Clare Wilhelm, Rebecca W Repetti, Jason C. Chang, Soo-Ryum Yang +10 more

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology(2025)10.1002/1878-0261.70155

N/A

0DataRank · unranked

0 citations

Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo +9 more

ALK Inhibitor Response in Novel ZFPM2::ALK and TRIM24::ALK Fusion-Positive Lung Cancers: Case Report

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100934

N/A

0DataRank · unranked

0 citations

Mohamed A. Yakoub, Michael Offin, Juliana Eng, Alexander Drilon, Soo-Ryum Yang +1 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Characterization of on-target adverse events caused by TRK inhibitor therapy

Annals of Oncology(2020)10.1016/j.annonc.2020.05.006

N/A

0DataRank · unranked

86 citations

James Flory, Andrew Lin, Michael Offin, Christina J. Falcon, Yonina R. Murciano‐Goroff +16 more

Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations

Journal of Molecular Diagnostics(2022)10.1016/j.jmoldx.2022.03.006

N/A

0DataRank · unranked

17 citations

Jada Barbee, Soo‐Ryum Yang, Jason C. Chang, Priscilla Liang, Kerry Mullaney +9 more

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.06.008

N/A

0DataRank · unranked

47 citations

Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm +12 more

Alexander Drilon

Indexed papers

Top data-sharing exemplar

Papers